folder

Evidence for the participation of kinins in Freund's adjuvant-induced inflammatory and nociceptive responses in kinin B1 and B2 receptor knockout mice

Authors

  • J. Ferreira
  • M.M. Campos
  • J.B. Pesquero
  • R.C. Araújo
  • M. Bader
  • J.B. Calixto

Journal

  • Neuropharmacology

Citation

  • Neuropharmacology 41 (8): 1006-1012

Abstract

  • Experiments were designed to investigate the role of kinin B1 and B2 receptors in Freund's adjuvant (CFA)-induced inflammation and nociception responses by the use of B1 and B2 null mutant mice. Intradermal (i.d.) injection of CFA produced time-dependent and marked hyperalgesic responses in both ipsilateral and contralateral paws of wild-type mice. Gene disruption of the kinin B2 receptor did not interfere with CFA-induced hyperalgesia, but ablation of the gene of the B1 receptor reduced the hyperalgesia in both ipsilateral (48±13%, at 12 h) and contralateral (91±22%, at 12 h) paws. Treatment of wild-type mice with the selective B1 antagonist des-Arg9-[Leu8]-BK (150 nmol/kg, s.c.) reduced CFA-evoked thermal hyperalgesia, to an extent which was similar to that observed in mice lacking kinin B1 receptor. I.d. injection of CFA produced a time-related and long-lasting (up to 72 h) increase in paw volume in wild-type mice. A similar effect was observed in B1 knockout mice. In mice lacking B2 receptor, the earlier stage of the CFA-induced paw oedema (6 h) was significantly greater compared with the wild-type animals, an effect which was almost completely reversed (76±5%) by des-Arg9-[Leu8]-BK. This data demonstrates that kinin B1 receptor, but not B2 receptor, exerts a critical role in controlling the persistent inflammatory hyperalgesia induced by CFA in mice, while B2 receptor appears to have only a minor role in the amplification of the earlier stage of CFA-induced paw oedema formation. The results of the present study, taken together with those of previous studies, suggest that B1 receptor antagonists represent a potential target for the development of new drugs to treat persistent inflammatory pain.


DOI

doi:10.1016/S0028-3908(01)00142-3